-

SYMBOTIC INVESTIGATION ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates Claims On Behalf of Investors of Symbotic Inc. - SYM

NEW ORLEANS--(BUSINESS WIRE)--Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., is investigating claims on behalf of Fund Managers and Investors of Symbotic Inc. (NasdaqGM: SYM) with losses in excess of $5 million. Such investors are advised to contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email (lewis.kahn@ksfcounsel.com), or visit https://www.ksfcounsel.com/cases/nasdaqgm-sym/ to learn more.

The investigation concerns whether Symbotic and certain of its officers and/or directors have engaged in fraud, negligence or other unlawful business practices.

On November 27, 2024, pre-market, the Company disclosed that it would restate its fiscal year 2024 financial results as it had “identified errors in its revenue recognition related to cost overruns on certain deployments that will not be billable, which additionally impacted system revenue, income (loss) before income tax, net income (loss) and gross margin recognized in the second, third, and fourth quarters of fiscal year 2024.”

On this news, the price of Symbotic’s shares fell $13.41 per share, or 36%, to close at $24 per share on November 27, 2024.

About Kahn Swick & Foti, LLC

KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation’s premier boutique securities litigation law firms. KSF serves a variety of clients – including public institutional investors, hedge funds, money managers and retail investors – in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, Delaware, California, Louisiana, Chicago and New Jersey.

To learn more about KSF, you may visit www.ksfcounsel.com.

Contacts

Kahn Swick & Foti, LLC
Lewis Kahn, Managing Partner
lewis.kahn@ksfcounsel.com
1-877-515-1850
1100 Poydras St., Suite 960
New Orleans, LA 70163

Industry:

Kahn Swick & Foti, LLC

NASDAQ:SYM
Release Versions
English

Contacts

Kahn Swick & Foti, LLC
Lewis Kahn, Managing Partner
lewis.kahn@ksfcounsel.com
1-877-515-1850
1100 Poydras St., Suite 960
New Orleans, LA 70163

More News From Kahn Swick & Foti, LLC

Esperion Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Esperion Therapeutics, Inc. - ESPR

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Esperion Therapeutics, Inc. (NasdaqGM: ESPR) to funds managed by ARCHIMED. Under the terms of the proposed transaction, shareholders of Esperion will receive $3.16 per share in cash and the right to participate in contingent milestone payments for each share of Esperion that they own. KSF is se...

Extreme Networks Investigation Continued: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Extreme Networks, Inc. - EXTR

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF continues its investigation into Extreme Networks, Inc. (NasdaqGS: EXTR). On January 31, 2024, the Company disclosed disappointing financial results and operational trends for 2Q24 including, among other things, that its revenues for the quarter were $296.4 million, down 7% year-over-year, and that it...

Soleno Therapeutics 96 Hour Deadline Alert: Kahn Swick & Foti, LLC Reminds Investors With Losses In Excess Of $100,000 of Deadline in Class Action Lawsuit Against Soleno Therapeutics, Inc. - SLNO

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Kahn Swick & Foti, LLC (“KSF”) and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until May 5, 2026 to file lead plaintiff applications in a securities class action lawsuit against Soleno Therapeutics, Inc. (“Soleno” or the “Company”) (NasdaqCM: SLNO), if they purchased or otherwise acquired the Company’s securities between March 26, 2025 and November 4, 2025, inclusive (the “Class Pe...
Back to Newsroom